What is a Cosmetic Product Safety Report (CPSR)?
A cosmetic product needs to be safe for human health when used under normal and reasonably foreseeable conditions of use. All cosmetic products placed on the EU market must be subject to a safety assessment conducted by a qualified person. A Cosmetic Product Safety Report (CPSR) shall be done and included in the Product Information File (PIF).
Marta Pinto

Marta Pinto

Regulatory Affairs Associate

EU LEGAL FRAMEWORK ON COSMETIC PRODUCTS

The Regulation (EC) No 1223/2009 establishes the rules that all cosmetic products made available on the European Union (EU) market must comply with, in order to ensure the functioning of the internal market and a high level of protection of human health.

Only cosmetic products for which a legal or natural person is designated as a “Responsible Person” (RP) can be placed on the EU market. The RP is fully responsible for safety and legal compliance. (see previous post)

According to Article 3 of this Regulation, “a cosmetic product made available on the market shall be safe for human health when used under normal or reasonably foreseeable conditions of use“. In order to demonstrate that a cosmetic product complies with Article 3, the RP must guarantee that the product has undergone a safety assessment and that a Cosmetic Product Safety Report (CPSR) is set up.

The CPSR must be carried out by a qualified safety assessor, with a university diploma (or other evidence of formal qualification) in pharmacy, toxicology, medicine or similar (recognized as equivalent by a Member State).

COSMETIC PRODUCT SAFETY REPORT (CPSR)

The CPSR consists of two parts (Part A and Part B) that should contain, as minimum, the following information:

  • PART A – Cosmetic product safety information
    • Quantitative and qualitative composition of the cosmetic product
    • Physical/chemical characteristics and stability of the cosmetic product
    • Microbiological quality
    • Impurities, traces, information about the packaging material
    • Normal and reasonably foreseeable use
    • Exposure to the cosmetic product
    • Exposure to the substances
    • Toxicological profile of the substances
    • Undesirable effects and serious undesirable effects
    • Information on the cosmetic product

  • PART B – Cosmetic product safety assessment
    • Assessment conclusion
    • Labelled warnings and instructions of use
    • Reasoning
    • Assessor’s credentials and approval of part B

The CPSR must be kept up to date, taking into acount relevant information generated after the product is placed on the market (e.g., amendments to Regulation).

The Cosmetic Product Safety Report is part of the Product Information File (PIF), which should be kept for a period of 10 years, counting on the date on which the last batch of the product was placed on the market.

In sum, the CPSR is a mandatory document for all cosmetic products in the EU, as it demonstrates the safety and efficacy of a cosmetic product.

Critical Catalyst has a team of qualified EU safety assessors with vast experience in conducting CPSRs. For more information, please feel free to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.

further
reading

cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »
medical devices

EUDAMED – harmonized practices and alternative solutions for IVDR until the database is fully functional

EUDAMED is one of the key aspects of the new rules on in vitro diagnostic medical devices – Regulation (EU) 2017/746. However, it is only expected to achieve full functionality by the second quarter of 2024. Until then, how is the information submitted and/or exchanged between manufacturers, notified bodies and competent authorities?

Read More »
medical devices

EUDAMED – update on timelines

EUDAMED is one of the key aspects of the new rules on medical devices (Regulation (EU) 2017/745) and in vitro diagnostic medical devices (Regulation (EU) 2017/746), and it is expected to achieve full functionality by the second quarter of 2024.

Read More »
cosmetic products

UK OPSS call for data on six cosmetic ingredients

On 14 July 2022, the Office for Product Safety and Standards (OPSS – the UK regulator for cosmetic products) issued a call for data on the safety of the following six cosmetic ingredients to investigate any suspected endocrine disrupting properties. 

Read More »
cosmetic products

European Commission Recommendation on the Definition of Nanomaterial

Nanomaterials are increasingly used in cosmetics and personal care products. They are similar to other chemicals/substances, but with specific risks associated to their use. The European Commission has published a new Recommendation to clarify the definition of ‘nanomaterial’. This definition may serve different policy, legislative and research purposes when addressing materials or issues concerning products of nanotechnologies.

Read More »
cosmetic products

Expected Restriction on the Use of Methyl Salicylate

The European Commission has notified the World Trade Organization (WTO) of a draft amendment to the Regulation (EC) No. 1223/2009 on cosmetic products. Annex III to Regulation will be amended, and the use of Methyl Salicylate in cosmetic products will be restricted.

Read More »